| CAS NO: | 1799753-84-6 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 5mg | 电议 |
| 10mg | 电议 |
| 25mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| 250mg | 电议 |
| Molecular Weight (MW) | 496.42 |
|---|---|
| Formula | C24H16F4N6O2 |
| CAS No. | 1799753-84-6 (BAY-876) |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility (In vitro) | DMSO: 99 mg/mL warmed (199.42 mM) |
| Water: <1 mg/mL | |
| Ethanol: 3 mg/mL warmed (6.04 mM) | |
| SMILES | O=C(C1=NC2=CC(F)=CC=C2C(C(NC3=C(C)N(CC4=CC=C(C=C4)C#N)N=C3C(F)(F)F)=O)=C1)N |
| Synonyms | BAY876; BAY 876; BAY-876 |
| In Vitro | In vitro activity: BAY-876 is a highly-selective GLUT1 inhibitor with selectivity over GLUT2, 3, and 4 of 4700-, 800-, and 135-fold, respectively. Kinase Assay: BAY-876 is a potent and highly-selective GLUT1 inhibitor with IC50 of 0.002 uM and with selectivity over GLUT2, 3, and 4 of 4700-, 800-, and 135-fold, respectively. Cell Assay: BAY-876 exhibited good metabolic stability in vitro and high oral bioavailability in vivo. GLUT1 overexpression has been reported in many types of human cancers, including those of brain,6 breast, colon, kidney, lung, ovary, and prostate, and is correlated with advanced cancer stages and poor clinical outcomes. Despite the long-known fact that the facilitative glucose transporter GLUT1 is one of the key players safeguarding the increase in glucose consumption of many tumor entities even under conditions of normal oxygen supply (known as the Warburg effect), only few endeavors have been undertaken to find a GLUT1-selective small-molecule inhibitor. |
|---|---|
| In Vivo | BAY-876 displays low clearance also in vivo in rat and in dog. The volume of distribution in steady state (Vss) is moderate in both species. Terminal half life is intermediate in rat (2.5 h) and long in dog (22 h) due to the very low clearance. The oral bioavailability (F%) is 85% and 79% in rat and dog, respectively. Preliminary in vivo PK studies of BAY-876 demonstrate that a good oral bioavailability and long terminal half-life is attainable making it an excellent chemical probe to further evaluate the hypothesis of cancer treatment with a very selective GLUT1 inhibitor. |
| Animal model | Rat and in dog |
| Formulation & Dosage | |
| References | ChemMedChem. 2016 Oct 19;11(20):2261-2271. |
m.cnreagent.com